Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Halozyme Therapeutics (NAS:HALO) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Halozyme Therapeutics Forward PE Ratio Related Terms
Halozyme Therapeutics Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Halozyme Therapeutics's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics Forward PE Ratio Chart
Halozyme Therapeutics Annual Data
Trend
2019-12
2020-12
2021-12
2023-12
2024-12
2025-12
Forward PE Ratio
18.35
29.67
23.04
9.03
9.96
8.47
Halozyme Therapeutics Quarterly Data
2019-09
2019-12
2020-03
2020-06
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2022-03
2022-06
2023-09
2023-12
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
30.40
18.35
26.74
24.27
21.79
29.67
27.78
34.72
21.79
23.04
17.42
24.04
9.43
9.03
13.07
16.64
13.76
9.96
12.37
9.50
9.26
8.47
7.69
HALO vs KYMR, IBRX, PRAX: Forward PE Ratio Comparison
For the Biotechnology subindustry, Halozyme Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Forward PE Ratio falls into.
Halozyme Therapeutics Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Halozyme Therapeutics (HALO) has a Forward PE Ratio of 10.06 as of Jul. 26, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Halozyme Therapeutics and its competitors. According to the industry distribution chart, Halozyme Therapeutics ranks #97 out of 354 companies in the Biotechnology industry, placing it in the top 27.4%.
Is Halozyme Therapeutics' Forward PE Ratio too high?
Halozyme Therapeutics' current Forward PE Ratio is 10.06. The Biotechnology industry median Forward PE Ratio is 21.88. Halozyme Therapeutics' value of 10.06 is 54% below this industry median. Based on the distribution chart, Halozyme Therapeutics ranks #97 out of 354 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Halozyme Therapeutics has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Forward PE Ratio compare to KYMR and IBRX?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #97 out of 354 companies for Forward PE Ratio. This puts Halozyme Therapeutics in the upper half of its industry. The industry median Forward PE Ratio is 21.88. Halozyme Therapeutics' value of 10.06 is 54% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 21.88, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Halozyme Therapeutics's current Forward PE Ratio of 10.06 is 54% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Halozyme Therapeutics and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 21.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Halozyme Therapeutics's current Forward PE Ratio is 10.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $91.89, compared to a current price of $81.91 — trading 10.9% below its estimated fair value. The current Forward PE Ratio is 10.06 and 54% below the Biotechnology industry median of 21.88. Halozyme Therapeutics' overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Forward PE Ratio is 10.06 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued.
The current stock price of $81.91 is trading 10.9% below its estimated GF Value™ of $91.89.
GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.
Key valuation signals for HALO:
Forward PE Ratio: 10.06
GF Value™: $91.89 vs. price of $81.91 (10.9% below fair value)
Industry Position: 54% below the Biotechnology median (#97 of 354)
No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
93GF Score
Get the complete analysis for HALO
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HALO has been successfully added to your 
